Trials / Completed
CompletedNCT00328432
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
Phase IB Study of Biomarker Modulation by Celecoxib vs. Placebo in Women With Newly-Diagnosed Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- University of Kansas · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.
Detailed description
A double blind randomized study of celecoxib 400 mg bid versus placebo in newly diagnosed breast cancer. Assessment of modulation of tissue markers (Ki-67, ER, VEGF, PR, etc.) and serum markers (estradiol, estrone, SHBG, etc.).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | celecoxib 400 mg bid |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-12-01
- First posted
- 2006-05-22
- Last updated
- 2008-09-17
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00328432. Inclusion in this directory is not an endorsement.